IP Library › Granted Patent US 9,044,430
Granted Patent B2
US 9,044,430 · App. 13/423,171 · Granted Jun 2, 2015

Allogeneic microvascular tissue for soft tissue treatments

Inventors: Dale R. Peterson (Carlsbad, CA); Richard B. Emmitt (Oldwick, NJ)
Assignee: MicroVascular Tissues, Inc.
A61K35/12A61K35/35C12N5/0653A61K35/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,044,430
App. No.
13/423,171
Granted
Jun 2, 2015
Kind
B2
Abstract

Disclosed are products and methods for treating soft tissue injuries. The provided methods include the production of processed or cryopreserved microvascular tissue. Also provided are products and methods of using processed or cryopreserved microvascular tissue for the treatment of soft tissue injuries.

Claims (12)

1. A composition comprising a plurality of uncultured stem or progenitor cells having intact cell membranes,

wherein the viability of said plurality of uncultured stem or progenitor cells having intact cell membranes is less than 50%,

wherein said composition is formulated for implantation into an allogeneic or xenogeneic recipient, and

wherein said composition has tissue healing activity and comprises no bone or bone-derived matrix.

2. The composition of claim 1 , wherein said plurality of uncultured allogeneic stem or progenitor cells are included in a processed or cryopreserved microvascular tissue.

3. The composition of claim 1 , wherein said plurality of uncultured stem or progenitor cells contains substantially no viable cells.

4. The composition of claim 1 , wherein said composition is stable at room temperature and retains tissue healing activity for at least one month.

5. The composition of claim 1 , wherein said tissue healing activity comprises improved healing of a soft or hard tissue exposed to the composition as compared to an analogous tissue similarly treated but without exposure to the composition.

6. The composition of claim 1 , wherein said uncultured stem or progenitor cells have been dried or lyophilized.

7. The composition of claim 1 , wherein said composition further comprises an excipient.

8. The composition of claim 1 , wherein said composition further comprises an implantable scaffold.

9. The composition of claim 1 , wherein said plurality of uncultured stem or progenitor cells has been treated to prevent microbial contamination.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2014
From: TORNIER, INC.
To: MICROVASCULAR TISSUES, INC.
Reel/Frame 033769/0918 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2012
From: PETERSON, DALE R.; EMMITT, RICHARD B.
To: TORNIER, INC.
Reel/Frame 029008/0593 →
Continuity (2)
Provisional Application 61454367 · Mar 18, 2011
Related Publication 20130071358A1 · Mar 21, 2013